CSIMarket
 


Mimedx Group Inc   (MDXG)
Other Ticker:  
 
 

MDXG's Capital Expenditures Growth by Quarter and Year

Mimedx Group Inc 's Capital Expenditures results by quarter and year




MDXG Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 0.43 1.67 0.58 2.48
III Quarter September 1.56 0.35 0.55 0.65
II Quarter June 0.00 0.38 0.41 0.41
I Quarter March 0.63 0.12 1.94 1.01
FY   2.62 2.52 3.48 4.55



MDXG Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Mimedx Group Inc reported drop in Capital Expenditures in the fourth quarter 2023 by -74.43% to $ 0.43 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Mimedx Group Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures rise of 30.53%.

Looking into fourth quarter 2023 results within Medical Equipment & Supplies industry 7 other companies have achieved higher Capital Expenditures growth. While Mimedx Group Inc ' s Capital Expenditures meltdown of -74.43% ranks overall at the positon no. 118 in the fourth quarter 2023.




MDXG Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -74.43 % 187.93 % -76.61 % 254.29 %
III Quarter September 345.71 % -36.36 % -15.38 % 306.25 %
II Quarter June - -7.32 % 0 % 64 %
I Quarter March 425 % -93.81 % 92.08 % 55.38 %
FY   3.85 % -27.59 % -23.52 % 158.52 %

Financial Statements
Mimedx Group Inc 's fourth quarter 2023 Capital Expenditures $ 0.43 millions MDXG's Income Statement
Mimedx Group Inc 's fourth quarter 2022 Capital Expenditures $ 1.67 millions Quarterly MDXG's Income Statement
New: More MDXG's historic Capital Expenditures Growth >>


MDXG Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -72.63 % 377.14 % 5.45 % 281.54 %
III Quarter September - -7.89 % 34.15 % 58.54 %
II Quarter June - 216.67 % -78.87 % -59.41 %
I Quarter March -62.28 % -79.31 % -21.77 % 44.29 %
FY (Year on Year)   3.85 % -27.59 % -23.52 % 158.52 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #8
Healthcare Sector #19
Overall #118

Capital Expenditures Y/Y Growth Statistics
High Average Low
273.71 % 30.53 % -81.41 %
(Dec. 30, 2013)   (Dec 31 2019)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #8
Healthcare Sector #19
Overall #118
Capital Expenditures Y/Y Growth Statistics
High Average Low
273.71 % 30.53 % -81.41 %
(Dec. 30, 2013)   (Dec 31 2019)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Mimedx Group Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
377.65 % 19.32 % -100 %
(Dec 31 2022)  


MDXG's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Mimedx Group Inc disclosed fall in Capital Expenditures sequentially by -72.63% to $ 0.43 millions, from $ 1.56 millions released in the previous quarter.

Albeit periodic circumstance usually elevate IV. Quarter 2023 results, this simply could not be sufficient to salvage Medical Equipment & Supplies's company outcome, Tuur Wouters, Medical Equipment & Supplies industry contributor said.

Within Medical Equipment & Supplies industry 65 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Mimedx Group Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1478.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #66
Healthcare Sector #185
Overall #1478
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #66
Healthcare Sector #185
Overall #1478
Capital Expenditures Q/Q Growth Statistics
High Average Low
377.65 % 19.32 % -100 %
(Dec 31 2022)  


MDXG's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Mimedx Group Inc reported fall in Capital Expenditures from the previous quarter by -72.63% to $ 0.43 millions, from $ 1.56 millions declared in the previous quarter.

Although periodic circumstance usually fuel IV. Quarter 2023 results, that plainly could not be sufficient to rescue Medical Equipment & Supplies's company IV. Quarter 2023 achievement, Tuur Wouters, Medical Equipment & Supplies industry contributor pointed out.

Within Medical Equipment & Supplies industry 65 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Mimedx Group Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1478.


Mimedx Group Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 3.03 $ 2.51
Y / Y Capital Expenditures Growth (TTM) - - - 83.91 % -27.55 %
Year on Year Capital Expenditures Growth Overall Ranking # 1083 # 364 # 460 # 478 # 1563
Seqeuential Capital Expenditures Change (TTM) - - - 20.49 % 76.54 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 118 # 1651 # 327 # 465 # 1656




Cumulative Capital Expenditures growth Comment
Mimedx Group Inc realized trailing twelve months Capital Expenditures of $ 0 millions, in the Dec 31 2023, compare to Capital Expenditures of $ 3 millions a year ago.

In the Healthcare sector 128 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 364 to 1083.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
273.71 %
30.53 %
-81.41 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 8
Healthcare Sector # 129
Overall # 1083

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
273.71 %
30.53 %
-81.41 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 19
S&P 500 # 118
Cumulative Capital Expenditures growth Comment
Mimedx Group Inc realized trailing twelve months Capital Expenditures of $ 0 millions, in the Dec 31 2023, compare to Capital Expenditures of $ 3 millions a year ago.

In the Healthcare sector 128 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 364 to 1083.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
273.71 %
30.53 %
-81.41 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 8
Healthcare Sector # 129
Overall # 1083

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
273.71 %
30.53 %
-81.41 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 19
S&P 500 # 118




Other Capital Expenditures Growth
Medical Equipment & Supplies Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
MDXG's Capital Expenditures Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for MDXG's Competitors
Capital Expenditures Growth for Mimedx Group Inc 's Suppliers
Capital Expenditures Growth for MDXG's Customers

You may also want to know
MDXG's Annual Growth Rates MDXG's Profitability Ratios MDXG's Asset Turnover Ratio MDXG's Dividend Growth
MDXG's Roe MDXG's Valuation Ratios MDXG's Financial Strength Ratios MDXG's Dividend Payout Ratio
MDXG's Roa MDXG's Inventory Turnover Ratio MDXG's Growth Rates MDXG's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Sunshine Biopharma Inc -0.43%$ -0.431 millions
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Alpine Immune Sciences Inc -1.72%$ -1.724 millions
Argenx se-2.99%$ -2.987 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions
Genedx Holdings Corp -16.28%$ -16.279 millions
Dexcom Inc -17.32%$ -17.323 millions
Davita Inc -17.74%$ -17.739 millions
Voyager Therapeutics Inc -19.08%$ -19.078 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com